Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses

Molecular Therapy

Volumn 17, Issue 4, 2009, Pages 697-706

  Zamarin, Dmitriy ^a,b   Martínez Sobrido, Luis ^a   Kelly, Kaitlyn ^b   Mansour, Mena ^a   Sheng, Gang ^b   VigilA, Adam ^a   García Sastre, Adolfo ^a   Palese, Peter ^a   Fong, Yuman ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; NONSTRUCTURAL PROTEIN 1; ONCOLYTIC VIRUS; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXIC LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNOMODULATION; INNATE IMMUNITY; LYMPHOCYTIC INFILTRATION; MELANOMA; MOUSE; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; VIRAL GENE DELIVERY SYSTEM;

ANIMALIA; MURINAE; MUS; NEWCASTLE DISEASE VIRUS;

EID: 63949087329     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.286     Document Type: Article

References (50)

1. Alexander, DJ (1988). Newcastle Disease, Newcastle Disease Virus - An Avian Paramyxovirus. Kluwer Academic: Dordrecht, the Netherlands. pp 1-22.
2. Sinkovics, JG and Horvath, JC (2000). Newcastle disease virus (NDV): brief history of its oncolytic strains. J Clin Virol 16: 1-15.
3. Karcher, J, Dyckhoff, G, Beckhove, P, Reisser, C, Brysch, M, Ziouta, Y et al. (2004). Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells. Cancer Res 64: 8057-8061.
4. Liang, W, Wang, H, Sun, TM, Yao, WQ, Chen, LL, Jin, Y et al. (2003). Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract. World J Gastroenterol 9 495-498.
5. Schneider, T, Gerhards, R, Kirches, E and Firsching, R (2001). Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme. J Neurooncol 53: 39-46.
6. Steiner, HH, Bonsanto, MM, Beckhove, P, Brysch, M, Geletneky, K, Ahmadi, R et al. (2004). Antitumor vaccination of patients with glioblastoma multiforme: A pilot study to assess feasibility, safety, and clinical benefit. J Clin Oncol 22: 4272-4281.
7. Cassel, WA and Murray, DR (1988). Treatment of stage II malignant melanoma patients with a Newcastle disease virus oncolysate. Nat Immun Cell Growth Regul 7: 351-352.
8. Batliwalla, FM, Bateman, BA, Serrano, D, Murray, D, Macphail, S, Maino, VC et al. (1998). A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire. Mol Med 4: 783-794.
9. Wallack, MK, Sivanandham, M, Balch, CM, Urist, MM, Bland, KI, Murray, D et al. (1998). Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: The final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 187: 69-77; discussion 77-69.
10. Ockert, D, Schirrmacher, V, Beck, N, Stoelben, E, Ahlert, T, Flechtenmacher, J et al. (1996). Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin Cancer Res 2: 21-28.
11. Schlag, P, Manasterski, M, Gerneth, T, Hohenberger, P, Dueck, M, Herfarth, C et al. (1992). Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial. Cancer Immunol Immunother 35: 325-330.
12. Lorence, RM, Roberts, MS, O'Neil, JD, Groene, WS, Miller, JA, Mueller, SN et al. (2007). Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus. Curr Cancer Drug Targets 7: 157-167.
13. Hotte, SJ, Lorence, RM, Hirte, HW, Polawski, SR, Bamat, MK, O'Neil, JD et al. (2007). An optimized clinical regimen for the oncolytic virus PV701. Clin Cancer Res 13: 977-985.
14. Freeman, AI, Zakay-Rones, Z, Gomori, JM, Linetsky, E, Rasooly, L, Greenbaum, E et al. (2006). Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 13: 221-228.
15. Pecora, AL, Rizvi, N, Cohen, GI, Meropol, NJ, Sterman, D, Marshall, JL et al. (2002). Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 20: 2251-2266.
16. Csatary, LK, Gosztonyi, G, Szeberenyi, J, Fabian, Z, Liszka, V, Bodey, B et al. (2004). MTH-68/H oncolytic viral treatment in human high-grade gliomas. J Neurooncol 67: 83-93.
17. Romer-Oberdorfer, A, Mundt, E, Mebatsion, T, Buchholz, UJ and Mettenleiter, TC (1999). Generation of recombinant lentogenic Newcastle disease virus from cDNA. J Gen Virol 80 (Pt 11): 2987-2995.
18. Nakaya, T, Cros, J, Park, MS, Nakaya, Y, Zheng, H, Sagrera, A et al. (2001). Recombinant Newcastle disease virus as a vaccine vector. J Virol 75: 11868-11873.
19. Peeters, BP, de Leeuw, OS, Koch, G and Gielkens, AL (1999). Rescue of Newcastle disease virus from cloned cDNA: Evidence that cleavability of the fusion protein is a major determinant for virulence. J Virol 73: 5001-5009.
20. Krishnamurthy, S, Takimoto, T, Scroggs, RA and Portner, A (2006). Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J Virol 80: 5145-5155.
21. Fiola, C, Peeters, B, Fournier, P, Arnold, A, Bucur, M and Schirrmacher, V (2006). Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence. Int J Cancer 119: 328-338.
22. Park, MS, Garcia-Sastre, A, Cros, JF, Basler, CF and Palese, P (2003). Newcastle disease virus V protein is a determinant of host range restriction. J Virol 77: 9522-9532.
23. Huang, Z, Krishnamurthy, S, Panda, A and Samal, SK (2003). Newcastle disease virus V protein is associated with viral pathogenesis and functions as an a interferon antagonist. J Virol 77: 8676-8685.
24. Vigil, A, Park, MS, Martinez, O, Chua, MA, Xiao, S, Cros, JF et al. (2007). Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res 67: 8285-8292.
25. Mibayashi, M, Martinez-Sobrido, L, Loo, YM, Cardenas, WB, Gale, M Jr and Garcia-Sastre, A (2007). Inhibition of retinoic acid-inducible gene I-mediated induction of β interferon by the NS1 protein of influenza A virus. J Virol 81: 514-524.
26. Wang, X, Li, M, Zheng, H, Muster, T, Palese, P, Beg, AA et al. (2000). Influenza A virus NS1 protein prevents activation of NF-κB and induction of α/β interferon. J Virol 74: 11566-11573.
27. Garcia-Sastre, A, Egorov, A, Matassov, D, Brandt, S, Levy, DE, Durbin, JE et al. (1998). Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology 252: 324-330.
28. Palese, P and Shaw, M (2007). Orthomyxoviridae: The virus and their replication. In: Fields, BN, KD, Howley, PM (eds). Field's Virology vol. 2. Lippincott Williams & Wilkins: Philadelphia. pp. 1647-1689.
29. Noah, DL, Twu, KY and Krug, RM (2003). Cellular antiviral responses against influenza A virus are countered at the posttranscriptional level by the viral NS1A protein via its binding to a cellular protein required for the 3′ end processing of cellular pre-mRNAS. Virology 307 386-395.
30. Vigil, A, Martinez, O, Chua, MA and Garcia-Sastre, A (2008). Recombinant Newcastle disease virus as a vaccine vector for cancer therapy. Mol Ther 16: 1883-1890.
31. Talon, J, Horvath, CM, Polley, R, Basler, CF, Muster, T, Palese, P et al. (2000). Activation of interferon regulatory factor 3 is inhibited by the influenza A virus NS1 protein. J Virol 74: 7989-7996.
32. Bergmann, M, Romirer, I, Sachet, M, Fleischhacker, R, Garcia-Sastre, A, Palese, P et al. (2001). A genetically engineered influenza A virus with ras-dependent oncolytic properties. Cancer Res 61 8188-8193.
33. Zhirnov, OP, Konakova, TE, Wolff, T and Klenk, HD (2002). NS1 protein of influenza A virus down-regulates apoptosis. J Virol 76: 1617-1625.
34. Stasakova, J, Ferko, B, Kittel, C, Sereinig, S, Romanova, J, Katinger, H et al. (2005). Influenza A mutant viruses with altered NS1 protein function provoke caspase-1 activation in primary human macrophages, resulting in fast apoptosis and release of high levels of interleukins 1β and 18. J Gen Virol 86: 185-195.
35. Poste, G, Doll, J, Hart, IR and Fidler, IJ (1980). In vitro selection of murine B16 melanoma variants with enhanced tissue-invasive properties. Cancer Res 40: 1636-1644.
36. Lee, YS, Kim, JH, Choi, KJ, Choi, IK, Kim, H, Cho, S et al. (2006). Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model. Clin Cancer Res 12: 5859-5868.
37. Entin, I, Plotnikov, A, Korenstein, R and Keisari, Y (2003). Tumor growth retardation, cure, and induction of antitumor immunity in B16 melanoma-bearing mice by low electric field-enhanced chemotherapy. Clin Cancer Res 9: 3190-3197.
38. Rochlitz, C, Dreno, B, Jantscheff, P, Cavalli, F, Squiban, P, Acres, B et al. (2002). Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: Phase II randomized study comparing two dose levels. Cancer Gene Ther 9 289-295.
39. Seliger, B, Wollscheid, U, Momburg, F, Blankenstein, T and Huber, C (2001). Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res 61: 1095-1099.
40. Muster, T, Rajtarova, J, Sachet, M, Unger, H, Fleischhacker, R, Romirer, I et al. (2004). Interferon resistance promotes oncolysis by influenza virus NS1-deletion mutants. Int J Cancer 110: 15-21.
41. Haralambieva, I, Iankov, I, Hasegawa, K, Harvey, M, Russell, SJ and Peng, KW (2007). Engineering oncolytic measles virus to circumvent the intracellular innate immune response. Mol Ther 15: 588-597.
42. Geiss, GK, Salvatore, M, Tumpey, TM, Carter, VS, Wang, X, Basler, CF et al. (2002). Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: The role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza. Proc Natl Acad Sci USA 99 10736-10741.
43. Park, MS, Steel, J, Garcia-Sastre, A, Swayne, D and Palese, P (2006). Engineered viral vaccine constructs with dual specificity: Avian influenza and Newcastle disease. Proc Natl Acad Sci USA 103: 8203-8208.
44. de Leeuw, OS, Koch, G, Hartog, L, Ravenshorst, N and Peeters, BP (2005). Virulence of Newcastle disease virus is determined by the cleavage site of the fusion protein and by both the stem region and globular head of the haemagglutinin-neuraminidase protein. J Gen Virol 86: 1759-1769.
45. Shin, EJ, Chang, JI, Choi, B, Wanna, G, Ebert, O, Genden, EM et al. (2007). Fusogenic vesicular stomatitis virus for the treatment of head and neck squamous carcinomas. Otolaryngol Head Neck Surg 136: 811-817.
46. Rivetz, B and Lipkind, M (1985). Interaction of Newcastle disease virus strains differing in virulence with chicken red blood cell receptors. Arch Virol 85: 231-255.
47. Suzuki, Y (2005). Sialobiology of influenza: Molecular mechanism of host range variation of influenza viruses. Biol Pharm Bull 28: 399-408.
48. Schirrmacher, V, Griesbach, A and Ahlert, T (2001). Antitumor effects of Newcastle disease virus in vivo: Local versus systemic effects. Int J Oncol 18: 945-952.
49. Phuangsab, A, Lorence, RM, Reichard, KW, Peeples, ME and Walter, RJ (2001). Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration. Cancer Lett 172: 27-36.
50. Quinlivan, M, Zamarin, D, Garcia-Sastre, A, Cullinane, A, Chambers, T and Palese, P (2005). Attenuation of equine influenza viruses through truncations of the NS1 protein. J Virol 79: 8431-8439.